Ypsomed announced today that it agreed to sell its pen needle and blood glucose monitoring (BGM) businesses to Medical Technology and Devices (MTD).
With the transfer of these businesses, Ypsomed plans to focus its diabetes care business on insulin pumps. Specifically, it looks to the further development and marketing of the mylife Loop automated insulin pump solution.
As part of its growth strategy, Ypsomed expects to invest more than $110 million in the next four years to expand autoinjector manufacturing capacity.
Get the full story on our sister site, Drug Delivery Business News.